Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study

Arch Dermatol Res. 2024 May 11;316(5):154. doi: 10.1007/s00403-024-02879-4.
No abstract available

Keywords: Alopecia areata; Effectiveness; Generic tofacitinib; Safety; Treatment.

Publication types

  • Letter

MeSH terms

  • Adult
  • Alopecia Areata* / drug therapy
  • Alopecia Areata* / economics
  • Cost-Benefit Analysis*
  • Drugs, Generic* / adverse effects
  • Drugs, Generic* / economics
  • Drugs, Generic* / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Piperidines* / adverse effects
  • Piperidines* / economics
  • Piperidines* / therapeutic use
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / economics
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines* / adverse effects
  • Pyrimidines* / economics
  • Pyrimidines* / therapeutic use
  • Pyrroles* / adverse effects
  • Pyrroles* / economics
  • Pyrroles* / therapeutic use
  • Retrospective Studies
  • Treatment Outcome
  • Young Adult

Substances

  • tofacitinib
  • Piperidines
  • Pyrimidines
  • Drugs, Generic
  • Pyrroles
  • Protein Kinase Inhibitors